Financial Markets
Medicaid Enrollment Soared by 25% During the COVID-19 Pandemic
Medicaid, the government-funded U.S. health insurer for people with low incomes, grew by about 25% between February 2020 and May...
Read more
Hearing Aids for the Masses
Select over the counter hearing aids will be available soon. The move aims to lower costs. Instead, it will reveal...
Read more
Amazon’s Clinical Tell
Amazon acquired One Medical, a chain of concierge primary care clinics. The move expands Amazon's presence in virtual primary care....
Read more
Prescriptions Cause Inflation?
Many point to rising drug costs as one cause of inflation. But drug costs do not affect consumer pricing, as...
Read more
A Price on Patient Values
Policy makers believe price transparency will help patients make cost-effective decisions. But patient decisions are made through trust, not cost-savings.
Read more
Price Transparency Fallacy
We think disclosing the costs of clinical care will reduce overall costs. In reality, price transparency will increase the cost...
Read more
Medicare Advantage Versus Traditional Medicare
A report found most Medicare Advantage plans offer little value over traditional Medicare. We should now question the need for...
Read more
Repurposing Generic Drugs can Reduce Time and Cost to Develop New Treatments
Most of the time when drugs are repurposed for diseases or conditions they were not originally intended for, it is...
Read more
The Actual Cost of COVID-19
In between conspiracy and accounting resides the truth about the financial impact of COVID-19. As a systemic risk, it is...
Read more
Venture Growth is not Healthcare Growth
Growth is a curious thing. We know it when we see it, but we find it hard to replicate. This...
Read more
The Chronic Disease of Debt
Medical debt in the United States has reached pandemic proportions. It is now the largest source of debt in the...
Read more
Ninety Percent of Drugs Fail Clinical Trials
It takes 10 to 15 years and around $1 billion to develop a successful drug. Despite these investments in time...
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more